Periodontitis and etanercept discontinuation risk in anti-tumor necrosis factor-naive rheumatoid arthritis patients: A nationwide population-based cohort study

Journal of Clinical Rheumatology

Volumn 19, Issue 8, 2013, Pages 432-438

  Chen, Hsin Hua ^a,b,c,d   Chen, Der Yuan ^a,b,c,d   Lai, Kuo Lung ^a,b   Chen, Yi Ming ^a,b   Chou, Yiing Jenq ^b   Chou, Pesus ^b   Lin, Ching Heng ^a   Huang, Nicole ^b,e  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^d NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^e TAIPEI CITY HOSPITAL   (Taiwan)

Author keywords

Drug survival; Etanercept; Periodontitis; Rheumatoid arthritis; Risk

Indexed keywords

CYCLOSPORIN; ETANERCEPT; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; PREDNISOLONE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR INHIBITOR;

AGE DISTRIBUTION; AGED; ARTICLE; COHORT ANALYSIS; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; PERIODONTITIS; POPULATION RESEARCH; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; STATISTICAL SIGNIFICANCE; SURVIVAL TIME; TREATMENT DURATION;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COMORBIDITY; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; ISOXAZOLES; MALE; METHOTREXATE; MIDDLE AGED; PERIODONTITIS; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SULFASALAZINE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84889257035     PISSN: 10761608     EISSN: 15367355     Source Type: Journal    
DOI: 10.1097/RHU.0000000000000041     Document Type: Article

References (50)

1. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003;48:35-45. (Pubitemid 36091645)
2. Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med. 1997;337:141-147. (Pubitemid 27306284)
3. Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000;343:1594-1602.
4. Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004;363:675-681. (Pubitemid 38296553)
5. Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum. 2004;50:1400-1411. (Pubitemid 38608061)
6. Furst DE, Breedveld FC, Kalden JR, et al. Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003). Ann Rheum Dis. 2003;62(suppl 2):ii2-ii9.
7. Wolfe F. The epidemiology of drug treatment failure in rheumatoid arthritis. Baillieres Clin Rheumatol. 1995;9:619-632.
8. Guidelines for prescribing TNF-alpha blockers in adults with rheumatoid arthritis. London: British Society for Rheumatology, 2001. Available at: http://www.rheumatology.org.uk. Accessed May 1, 2013.
9. Marchesoni A, Zaccara E, Gorla R, et al. TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. Ann N Y Acad Sci. 2009;1173:837-846.
10. Iannone F, Gremese E, Atzeni F, et al. Longterm retention of tumor necrosis factor-alpha inhibitor therapy in a large Italian cohort of patients with rheumatoid arthritis from the GISEA registry: an appraisal of predictors. J Rheumatol. 2012;39:1179-1184.
11. Berthelot JM, Le Goff B. Rheumatoid arthritis and periodontal disease. Joint Bone Spine. 2010;77:537-541.
12. Ogrendik M. Rheumatoid arthritis is linked to oral bacteria: etiological association. Mod Rheumatol. 2009;19:453-456.
13. Nesse W, Dijkstra PU, Abbas F, et al. Increased prevalence of cardiovascular and autoimmune diseases in periodontitis patients: a cross-sectional study. J Periodontol. 2010;81:1622-1628.
14. Mercado F, Marshall RI, Klestov AC, et al. Is there a relationship between rheumatoid arthritis and periodontal disease? J Clin Periodontol. 2000;27:267-272.
15. Rosenstein ED, Greenwald RA, Kushner LJ, et al. Hypothesis: the humoral immune response to oral bacteria provides a stimulus for the development of rheumatoid arthritis. Inflammation. 2004;28:311-318. (Pubitemid 41504274)
16. de Pablo P, Dietrich T, McAlindon TE. Association of periodontal disease and tooth loss with rheumatoid arthritis in the US population. J Rheumatol. 2008;35:70-76.
17. Saini R, Marawar PP, Shete S, et al. Periodontitis, a true infection. J Glob Infect Dis. 2009;1:149-150.
18. Albandar JM. Underestimation of periodontitis in NHANES surveys. J Periodontol. 2011;82:337-341.
19. Pischon N, Pischon T, Kroger J, et al. Association among rheumatoid arthritis, oral hygiene, and periodontitis. J Periodontol. 2008;79:979-986.
20. Dissick A, Redman RS, Jones M, et al. Association of periodontitis with rheumatoid arthritis: a pilot study. J Periodontol. 2010;81:223-230.
21. Potikuri D, Dannana KC, Kanchinadam S, et al. Periodontal disease is significantly higher in non-smoking treatment-naive rheumatoid arthritis patients: results from a case-control study. Ann Rheum Dis. 2012;71:1541-1544.
22. Chen HH, Huang N, Chen YM, et al. Association between a history of periodontitis and the risk of rheumatoid arthritis: a nationwide, population-based, case-control study [published online ahead of print August 31, 2012]. Ann Rheum Dis.
23. Arkema EV, Karlson EW, Costenbader KH. A prospective study of periodontal disease and risk of rheumatoid arthritis. J Rheumatol. 2010;37:1800-1804.
24. Routsias JG, Goules JD, Goules A, et al. Autopathogenic correlation of periodontitis and rheumatoid arthritis. Rheumatology (Oxford). 2011;50:1189-1193.
25. Abou-Raya A, Abou-Raya S, Abu-Elkheir H. Periodontal disease and rheumatoid arthritis: is there a link? Scand J Rheumatol. 2005;34:408-410. (Pubitemid 41545918)
26. McGraw WT, Potempa J, Farley D, et al. Purification, characterization, and sequence analysis of a potential virulence factor from Porphyromonas gingivalis, peptidylarginine deiminase. Infect Immun. 1999;67:3248-3256. (Pubitemid 29291488)
27. Schellekens GA, Visser H, de Jong BA, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum. 2000;43:155-163. (Pubitemid 30368225)
28. Ogrendik M. Rheumatoid arthritis is an autoimmune disease caused by periodontal pathogens. Int J Gen Med. 2013;6:383-386.
29. Ogrendik M, Kokino S, Ozdemir F, et al. Serum antibodies to oral anaerobic bacteria in patients with rheumatoid arthritis. MedGenMed. 2005;7:2.
30. van der Helm-van Mil AH, Verpoort KN, Breedveld FC, et al. Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. Arthritis Res Ther. 2005;7:R949-R958.
31. Nilsson M, Kopp S. Gingivitis and periodontitis are related to repeated high levels of circulating tumor necrosis factor-alpha in patients with rheumatoid arthritis. J Periodontol. 2008;79:1689-1696.
32. Marotte H, Farge P, Gaudin P, et al. The association between periodontal disease and joint destruction in rheumatoid arthritis extends the link between the HLA-DR shared epitope and severity of bone destruction. Ann Rheum Dis. 2006;65:905-909.
33. de Smit M, Westra J, Vissink A, et al. Periodontitis in established rheumatoid arthritis patients: a cross-sectional clinical, microbiological and serological study. Arthritis Res Ther. 2012;14:R222.
34. Al-Katma MK, Bissada NF, Bordeaux JM, et al. Control of periodontal infection reduces the severity of active rheumatoid arthritis. J Clin Rheumatol. 2007;13:134-137. (Pubitemid 46884200)
35. Ribeiro J, Leao A, Novaes AB. Periodontal infection as a possible severity factor for rheumatoid arthritis. J Clin Periodontol. 2005;32:412-416. (Pubitemid 40569605)
36. Ogrendik M, Hakguder A, Keser N. Treatment of rheumatoid arthritis with ornidazole. A randomized, double-blind, placebo-controlled study. Rheumatology (Oxford). 2006;45:636-637.
37. Ogrendik M. Levofloxacin treatment in patients with rheumatoid arthritis receiving methotrexate. South Med J. 2007;100:135-139. (Pubitemid 46213754)
38. Ogrendik M. Effects of clarithromycin in patients with active rheumatoid arthritis. Curr Med Res Opin. 2007;23:515-522. (Pubitemid 46456899)
39. Ortiz P, Bissada NF, Palomo L, et al. Periodontal therapy reduces the severity of active rheumatoid arthritis in patients treated with or without tumor necrosis factor inhibitors. J Periodontol. 2009;80:535-540.
40. Savioli C, Ribeiro AC, Fabri GM, et al. Persistent periodontal disease hampers anti-tumor necrosis factor treatment response in rheumatoid arthritis. J Clin Rheumatol. 2012;18:180-184.
41. Cheng TM. Taiwan's new national health insurance program: genesis and experience so far. Health Aff (Millwood). 2003;22:61-76.
42. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315-324. (Pubitemid 18091653)
43. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613-619.
44. Soderlin MK, Petersson IF, Geborek P. The effect of smoking on response and drug survival in rheumatoid arthritis patients treated with their first anti-TNF drug. Scand J Rheumatol. 2012;41:1-9.
45. Hyrich KL, Watson KD, Silman AJ, et al. Predictors of response to antiYTNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford). 2006;45:1558-1565. (Pubitemid 44817065)
46. Yang CT, Kuo CF, Luo SF, et al. Discontinuation of antiYTNF-alpha therapy in a Chinese cohort of patients with rheumatoid arthritis [published online ahead of print July 31, 2012]. Clin Rheumatol.
47. Sakai R, Tanaka M, Nanki T, et al. Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target molecules [published online ahead of print April 13, 2012]. Ann Rheum Dis.
48. Nassar PO, Felipetti FA, Nassar CA, et al. Evaluation of effect of cyclosporine a on the bone tissue with induced periodontal disease to ligature in rats. Transplant Proc. 2013;45:778-782.
49. Taiwan tobacco control 2007 annual report. Available at: http://tobacco.bhp.doh.gov.tw/Upload/Documents/52d6b56bba294c6480a1.pdf. Accessed June 1, 2007.
50. Chen HH, Chen DY. Health-related quality of life and disease-related costs: comparison between ankylosing spondylitis, rheumatoid arthritis and systemic lupus erythematosus in Taiwan. 2009. [Unpublished data].